Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $162.50 short put and a strike $157.50 long put offers a potential 25.31% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $162.50 by expiration. The full premium credit of $1.01 would be kept by the premium seller. The risk of $3.99 would be incurred if the stock dropped below the $157.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 62.8 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
The Zacks Analyst Blog Highlights: BioMarin, Prosensa, Five Prime Therapeutics, AbbVie, Amgen, Biogen and Vertex
Fri, 28 Nov 2014 13:34:06 GMT
AstraZeneca/Amgen's Brodalumab Excels in Psoriasis Study
Wed, 26 Nov 2014 21:30:02 GMT
Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
Tue, 25 Nov 2014 21:01:00 GMT
PR Newswire – THOUSAND OAKS, Calif. and LONDON, Nov. 25, 2014 /PRNewswire/ — Amgen (AMGN) and AstraZeneca (AZN) today announced that AMAGINE-2TM, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12. Brodalumab 210 mg given every two weeks and the brodalumab weight-based analysis group were each shown to be superior to Stelara on the primary endpoint of achieving total clearance of skin disease, as measured by the Psoriasis Area Severity Index (PASI 100). When compared with placebo, a significantly greater proportion of patients treated with brodalumab achieved at least a 75 percent improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75). Results showed that 44.4 percent of patients in the brodalumab 210 mg group, 33.6 percent of patients in the brodalumab weight-based group, 25.7 percent of patients in the brodalumab 140 mg group, 21.7 percent of patients in the Stelara group and 0.6 percent of patients in the placebo group achieved total clearance of skin disease (PASI 100).
Astellas announces termination of Amgen-sponsored clinical studies of rilotumumab in gastric cancer (pdf 76.0KB)
Tue, 25 Nov 2014 00:13:00 GMT
noodls – Microsoft Word – API_Rilo termination release draft 201425 en Astellas final (2) Astellas announces termination of Amgen-sponsored clinical studies of rilotumumab in gastric cancer Tokyo, November 25, …
Amgen ends studies of gastric cancer drug
Mon, 24 Nov 2014 18:28:39 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook